Thus, it is not surprising that, as supported by preclinical models in prostate cancer models, several ongoing clinical trials are evaluating Abiraterone or Enzalutamide in association with different PI3K inhibitors [259,260]. The gene discussed is PIK3CG; the disease is Familial prostate cancer.